Bone Marrow Transplant Clinical Trial - Sellas Life Science Group SLSG18-301

Status:

Open (Study open and enrolling)

ClinicalTrials.gov:

NCT04229979

CONDITION(S): Acute Myeloid Leukemia - TRIAL: Sellas Life Science Group SLSG18-301-GPS Compared With BAT in AML CR2/CR2p

To assess the safety and efficacy of galinpepimut-S compared with investigator's choice of best available therapy (BAT) on overall survival (OS) in subjects with acute myeloid leukemia (AML) who are in second complete remission 2 (CR2)/second complete remission with incomplete platelet recovery (CR2p).

Drug

Biological: Galinpepimut-SDrug: Best Available Therapy

Trial Type

Interventional

Condition

Acute Myeloid Leukemia